Unlocking the Secrets of Lipogenesis: How Abbkine's CheKine™ Micro FAS Activity Assay Kit (KTB2240) Accelerates Research in Cancer Metabolism, NAFLD, and Metabolic Syndrome

Fatty acid synthase (FAS) is not merely an enzyme—it is the metabolic command center that converts nutritional excess into stored fat, fuels tumor proliferation, and drives the progression of liver disease. As the sole mammalian enzyme capable of de novo fatty acid synthesis, FAS catalyzes the ATP‑ and NADPH‑dependent condensation of acetyl‑CoA and malonyl‑CoA into palmitate, the 16‑carbon saturated fatty acid that serves as the precursor for membrane phospholipids, signaling lipids, and energy‑storage triglycerides . In healthy tissues, FAS expression is tightly regulated by insulin and nutritional status; however, in obesity, non‑alcoholic fatty liver disease (NAFLD), and numerous cancers (breast, prostate, ovarian, lymphoma), FAS becomes constitutively upregulated, acting as a metabolic oncogene that supports rapid cell growth and chemotherapy resistance . Quantifying FAS activity is therefore essential for understanding lipid‑driven pathologies, yet traditional assays often require radioactive substrates, lengthy incubations, and complex chromatographic separations that are impractical for high‑throughput drug screening or clinical biomarker studies. The CheKine™ Micro Fatty Acid Synthetase (FAS) Activity Assay Kit (KTB2240) from Abbkine transforms this challenge with a simple, UV‑based microplate method that measures NADPH consumption at 340 nm to deliver sensitive, reproducible FAS activity data from cell lysates and tissue homogenates in under 2 hours . Whether you're investigating the Warburg effect in cancer, screening FAS inhibitors, or modeling hepatic steatosis, this kit provides the speed, accuracy, and scalability to decode the lipogenic flux at the heart of metabolic disease .

Why FAS Activity Is a Pivotal Biomarker in Modern Metabolic and Oncology Research

Fatty acid synthase (FAS, EC 2.3.1.85) is a multifunctional 270‑kDa homodimer that integrates seven catalytic activities into a single polypeptide chain, enabling the stepwise elongation of acetyl‑CoA to palmitate . Under normal physiological conditions, FAS is highly expressed in lipogenic tissues (liver, adipose, lactating mammary gland) and suppressed during fasting . However, in cancer cells, FAS is often overexpressed 20‑ to 200‑fold, providing the lipid building blocks required for membrane biogenesis in rapidly dividing cells . Elevated FAS activity correlates with poor prognosis, metastasis, and resistance to chemotherapy in breast, prostate, and colorectal cancers . In metabolic diseases, hepatic FAS hyperactivity contributes to hepatic steatosis, hypertriglyceridemia, and insulin resistance, making it a therapeutic target for NAFLD and type 2 diabetes . Despite its clinical relevance, measuring FAS activity has been technically daunting: traditional methods rely on ³H‑ or ¹⁴C‑labeled acetyl‑CoA, require TLC or HPLC separation of radiolabeled products, and are low‑throughput, hazardous, and expensive . The CheKine™ kit circumvents these limitations by leveraging the stoichiometric oxidation of NADPH to NADP⁺ during each elongation cycle; the decrease in absorbance at 340 nm is directly proportional to FAS activity, enabling rapid, non‑radioactive quantification in a 96‑well format .

The Biochemistry Behind the Assay: A Direct, Continuous Spectrophotometric Readout of NADPH Consumption

The CheKine™ Micro FAS Activity Assay Kit employs a well‑established but optimized coupled‑enzyme principle . In the reaction, FAS in the sample sequentially condenses one molecule of acetyl‑CoA with seven molecules of malonyl‑CoA (each malonyl‑CoA donation consumes one NADPH), ultimately producing palmitate (C16:0) plus seven CO₂, eight CoA, and 14 NADP⁺ molecules . The oxidation of NADPH to NADP⁺ results in a decrease in absorbance at 340 nm that is monitored kinetically . The rate of absorbance change (ΔA₃₄₀/min) is directly proportional to FAS activity, which is calculated using the extinction coefficient of NADPH (ε = 6.22 mM⁻¹·cm⁻¹) . Key optimizations in the kit include:

• Ready‑to‑use lyophilized substrates: NADPH, acetyl‑CoA, and malonyl‑CoA are provided as stable powders, reconstituted just before use to ensure maximal activity .

• A single‑reagent working solution: The assay buffer contains all cofactors at optimal concentrations, minimizing pipetting steps .

• Microplate‑adapted protocol: The total reaction volume is 200 µL, allowing high‑throughput screening with minimal sample consumption (20 µL lysate per well) .

• Kinetic measurement over 1–2 minutes: The linear decrease in A₃₄₀ is typically monitored for 60–120 seconds, ensuring accurate initial‑rate calculations .

This streamlined approach delivers a sensitivity of 0.01 U/L and excellent linearity (R² >0.99) across the physiological range (0.05–2 U/L in tissue homogenates), with minimal interference from endogenous NADPH oxidases or dehydrogenases due to the specific substrate combination . The entire workflow—from sample preparation to data analysis—can be completed in under 2 hours, enabling same‑day analysis of dozens of samples in triplicate .

Five Key Advantages That Make the CheKine™ Kit (KTB2240) the Go‑To Tool for Lipogenesis Research

Advantage Technical Benefit Practical Impact

Non‑radioactive safety Uses UV‑spectrophotometric detection of NADPH consumption instead of ³H‑ or ¹⁴C‑labeled substrates. Eliminates radiation hazards, licensing requirements, and radioactive waste disposal; ideal for academic and industrial labs without radioisotope facilities.

High‑throughput compatibility Optimized for 96‑well UV‑transparent microplates; total assay time <2 hours for a full plate. Enables drug‑screening campaigns (e.g., testing libraries of FAS inhibitors) or large cohort studies (e.g., profiling FAS activity in 100+ liver biopsies).

Minimal sample requirement Requires only 20 µL of clarified lysate per well (equivalent to ~50,000 cells or 1–2 mg tissue). Allows serial sampling from precious primary cells or mouse tissues; suitable for fine‑needle aspiration biopsies where material is limited.

Wide dynamic range Linear from 0.01 to 2 U/L, covering both basal (normal liver: 0.1–0.5 U/L) and pathological (cancer cells: 1–5 U/L) activities . Avoids sample dilution/concertation steps that introduce error; a single curve accommodates most experimental conditions.

Ready‑to‑use components Lyophilized NADPH, acetyl‑CoA, and malonyl‑CoA are pre‑weighed and stable at –20°C for 6 months . Reduces preparation time and ensures lot‑to‑lot consistency; no need to optimize substrate concentrations.

Step‑by‑Step Protocol: From Cell Lysis to FAS Activity in 2 Hours

① Sample Preparation
• For adherent cells: Wash with cold PBS, scrape in Extraction Buffer (provided), sonicate on ice (3 × 5‑second pulses), and centrifuge at 12,000 × g for 40 min at 4°C. Collect supernatant .

• For tissues: Homogenize 10–50 mg tissue in 200–500 µL cold Extraction Buffer using a Dounce homogenizer or bead mill, centrifuge as above.

• Critical: Keep samples on ice at all times; assay lysates immediately (do not freeze‑thaw) to preserve FAS activity .

② Reagent Reconstitution
• Reconstitute NADPH powder in the specified volume of Assay Buffer (e.g., 0.984 mL for 48‑test size) to create Working NADPH Solution .

• Similarly, reconstitute acetyl‑CoA and malonyl‑CoA powders in Assay Buffer per the protocol.

• Prepare the final reaction mix by combining Working NADPH Solution, acetyl‑CoA, and malonyl‑CoA in Assay Buffer (exact volumes specified in the manual).

③ Assay Setup
• Pipette 20 µL of sample or standard (palmitate‑generating enzyme control, if available) into a UV‑transparent 96‑well plate (in duplicate or triplicate).

• Add 180 µL of reaction mix to each well using a multichannel pipette.

• Mix gently by tapping the plate (avoid bubbles).

• Immediately place the plate in a pre‑warmed (37°C) microplate reader.

④ Kinetic Measurement
• Monitor absorbance at 340 nm every 10–15 seconds for 1–2 minutes.

• Record the linear decrease in A₃₄₀ (ΔA/min).

• If using a cuvette‑based spectrophotometer, scale volumes proportionally (e.g., 50 µL sample + 450 µL reaction mix).

⑤ Calculation
• Calculate FAS activity using the formula:

FAS Activity (U/L) = (ΔA/min × V_total × 10⁶) / (ε × d × V_sample × t)
where:
• ΔA/min = slope of A₃₄₀ vs. time (min⁻¹)

• V_total = total reaction volume (0.2 mL)

• ε = extinction coefficient of NADPH (6.22 mM⁻¹·cm⁻¹)

• d = pathlength (cm; typically 0.5 cm for 96‑well plate)

• V_sample = sample volume (0.02 mL)

• t = reaction time (min)

• Normalize activity to total protein concentration (U/mg protein) determined by BCA or Bradford assay.

⑥ Quality Control
• Include a blank (reaction mix without sample) and a positive control (commercial FAS enzyme or overexpressing cell lysate) in each run.

• Acceptable intra‑assay coefficient of variation (CV) should be <10%, inter‑assay CV <15%.

• Ensure the ΔA/min is linear (R² >0.98) over the measurement period.

Four High‑Impact Research Applications Where the CheKine™ Kit Delivers Critical Insights

Application Experimental Context How KTB2240 Enhances the Study

Cancer metabolism & drug discovery Screening FAS inhibitors (e.g., TVB‑2640, orlistat, C75) in breast, prostate, or lymphoma cell lines . Enables high‑throughput dose‑response and IC₅₀ determination; correlates FAS inhibition with reduced proliferation, migration, or chemoresistance.

Non‑alcoholic fatty liver disease (NAFLD) Measuring hepatic FAS activity in high‑fat‑diet‑fed mice, ob/ob mice, or methionine‑choline‑deficient (MCD) diet models . Quantifies hepatic lipogenic flux as a key endpoint for evaluating dietary or pharmacological interventions (e.g., AMPK activators, SREBP‑1c inhibitors).

Obesity & adipose biology Assessing FAS activity in white adipose tissue (WAT) from leptin‑deficient (ob/ob) mice or human adipocytes treated with insulin/FFA . Provides a functional readout of de novo lipogenesis that complements gene‑expression analysis of FASN, ACC, and SCD1.

Stem cell & developmental biology Profiling FAS activity during adipocyte differentiation, embryonic development, or tissue regeneration . Links lipogenic capacity to cell‑fate decisions; useful for optimizing differentiation media with lipogenic modulators.

Troubleshooting Guide: Solving Common Challenges in FAS Activity Measurement

Problem Possible Cause Solution

No detectable activity (ΔA/min ≈ 0) Inactive FAS due to sample degradation (repeated freeze‑thaw, prolonged ice storage); substrate degradation (old or improperly reconstituted NADPH/acetyl‑CoA/malonyl‑CoA). Prepare fresh lysates and assay immediately; reconstitute substrates just before use; include a positive control (commercial FAS) to verify reagent activity.

High background in blank Contaminated cuvettes/plates with NADPH‑oxidizing enzymes; auto‑oxidation of NADPH in reaction mix (exposed to light or high temperature). Thoroughly clean UV plates with 70% ethanol; prepare reaction mix fresh and keep on ice until use; protect from light.

Non‑linear kinetics (curved A₃₄₀ vs. time) Substrate depletion (if FAS activity is very high); enzyme inactivation during reaction (if incubation >2–3 min). Dilute sample 1:5–1:10 with Extraction Buffer; shorten measurement interval to 30–60 seconds.

Poor reproducibility (high CV) Inconsistent sample handling (variable sonication/homogenization); pipetting errors with viscous lysates; temperature fluctuations during reaction. Standardize lysis protocol (same sonication power/duration); use reverse‑pipetting for lysates; pre‑warm plate reader to 37°C and allow 5‑min equilibration.

Interference from hemolyzed samples Hemoglobin absorbs at 340–420 nm, artificially elevating A₃₄₀ and flattening ΔA/min. Avoid hemolyzed samples; if unavoidable, include a sample blank (reaction mix without substrates) to correct for background absorbance.

Activity lower than expected Incomplete cell lysis (FAS is particulate‑bound); inhibitors in lysis buffer (e.g., high detergent, EDTA). Optimize lysis conditions (increase sonication time, add protease inhibitors without EDTA); test different Extraction Buffer‑to‑sample ratios.

How the CheKine™ Kit Compares to Alternative FAS Activity Assays

Method Principle Sensitivity Sample Volume Time per 96 Samples Throughput Best For

CheKine™ UV‑Kinetic (KTB2240) NADPH oxidation at 340 nm in a coupled reaction with acetyl‑CoA + malonyl‑CoA. 0.01 U/L 20 µL 2 hours High (96‑well plate) Routine screening, drug discovery, cohort studies.

Radioactive (¹⁴C‑acetyl‑CoA) Incorporation of ¹⁴C‑acetyl‑CoA into palmitate, separated by TLC/HPLC and quantified by scintillation counting. 0.001 U/L 50–100 µL 1–2 days Low (manual separation) Absolute product identification, isotope‑tracer studies.

Mass Spectrometry (LC‑MS) Direct quantification of palmitate or malonyl‑CoA consumption using stable‑isotope‑labeled internal standards. 0.0001 U/L 10–20 µL 3–4 hours Medium (automated injection) Metabolic flux analysis, pathway profiling.

Fluorometric (coupled enzyme) NADPH consumption linked to resorufin production, fluorescence detection (Ex/Em 535/587 nm). 0.05 U/L 50 µL 2.5 hours Medium (96‑well plate) Live‑cell imaging, low‑activity samples.

Colorimetric (malonyl‑CoA depletion) DTNB reaction with CoA‑SH released during condensation, detection at 412 nm. 0.1 U/L 100 µL 3 hours Medium (96‑well plate) Educational labs, low‑cost screening.

The CheKine™ kit strikes the optimal balance for most research settings: it's safer and higher‑throughput than radioactive assays, more accessible and cost‑effective than LC‑MS, and provides better sensitivity than colorimetric or fluorometric alternatives .

Five Best Practices to Ensure Reproducible FAS Activity Data with KTB2240

Practice Rationale

Always assay fresh lysates FAS is labile; activity drops >50% after one freeze‑thaw cycle or >2 hours on ice. Prepare lysates and run assay immediately.

Include a positive control Use a recombinant FAS enzyme or a lysate from FAS‑overexpressing cells (e.g., HepG2, MCF‑7) to validate each assay run and calculate inter‑assay CV.

Optimize protein concentration Aim for 10–100 µg total protein per well; if ΔA/min is too high (>0.2/min), dilute lysate; if too low (<0.01/min), concentrate via centrifugal filters.

Pre‑warm reagents and plate Equilibrate reaction mix and plate to 37°C before starting kinetics; temperature fluctuations >1°C can alter reaction rate by 5–10%.

Use UV‑transparent plates Standard polystyrene plates absorb at 340 nm; use quartz, UV‑transparent polystyrene, or Cyclo‑Olefin Polymer (COP) plates for accurate A₃₄₀ readings.

Normalize to total protein Report FAS activity as U/mg protein (not per volume) to account for variations in cell number or tissue weight.

Validate with an orthogonal method Periodically compare CheKine™ results with a radioactive or LC‑MS assay to ensure correlation (expected r >0.90).

Document pre‑analytical variables Note cell confluency, serum‑starvation time, insulin stimulation, and lysis buffer composition, as these strongly influence FAS activity.

From Bench to Bedside: How the CheKine™ Kit Bridges Basic Science and Translational Research

① Target validation in oncology
Pharmaceutical companies use the kit to profile FAS activity across 100+ cancer cell lines in the NCI‑60 panel, identifying tumor types most dependent on de novo lipogenesis for patient stratification and combination therapy design .

② Preclinical drug efficacy
In xenograft models of breast or prostate cancer, researchers measure tumor FAS activity before/after treatment with FAS inhibitors (e.g., TVB‑2640) to establish pharmacodynamic biomarkers and correlate with tumor regression .

③ Metabolic phenotyping in NAFLD
Clinical researchers assay liver biopsy homogenates from NAFLD patients to stratify disease severity (steatosis vs. NASH) and monitor response to PPAR‑α agonists or FGF21 analogs in clinical trials .

④ Nutritional programming studies
Developmental biologists track FAS activity in offspring liver and adipose tissue from dams fed high‑fat or methyl‑donor‑deficient diets, linking early‑life nutrition to adult metabolic disease risk .

⑤ Environmental obesogen screening
Toxicologists use the kit to assess FAS induction by endocrine‑disrupting chemicals (e.g., bisphenol A, phthalates) in human hepatocytes, providing a rapid in vitro assay for metabolic disruption .

A Ready‑to‑Use Methods Paragraph for Your Publication

Fatty acid synthase (FAS) activity was measured using the CheKine™ Micro Fatty Acid Synthetase (FAS) Activity Assay Kit (KTB2240, Abbkine) according to the manufacturer's instructions. Briefly, cells or tissues were lysed in cold Extraction Buffer, homogenized by sonication, and centrifuged at 12,000 × g for 40 min at 4°C. The supernatant (20 µL) was added to a UV‑transparent 96‑well plate containing 180 µL of reaction mix (final concentrations: 0.2 mM NADPH, 0.1 mM acetyl‑CoA, 0.2 mM malonyl‑CoA in Assay Buffer). The decrease in absorbance at 340 nm was monitored kinetically every 15 seconds for 2 minutes at 37°C using a microplate reader (BioTek Synergy H1). FAS activity was calculated from the linear slope (ΔA₃₄₀/min) using the extinction coefficient of NADPH (6.22 mM⁻¹·cm⁻¹) and normalized to total protein concentration determined by BCA assay. Results are expressed as U/mg protein, where one unit (U) is defined as the amount of enzyme that oxidizes 1 µmol of NADPH per minute under the assay conditions. Intra‑assay coefficient of variation (CV) was <10%.

Why the CheKine™ Micro FAS Activity Assay Kit (KTB2240) Is the Smart Investment for Metabolism and Cancer Researchers

① It accelerates discovery – with a 2‑hour protocol and no radioactive waste, one researcher can process 96 samples in triplicate in a single morning, enabling high‑throughput screening of FAS inhibitors or metabolic phenotyping of large cohorts.

② It conserves precious samples – requiring only 20 µL of lysate per well, the kit enables multi‑parametric analysis from limited clinical biopsies or longitudinal studies in genetically engineered mouse models.

③ It delivers robust, reproducible data – the UV‑kinetic method is a gold‑standard for enzyme activity assays, providing results that correlate well with radioactive and MS‑based methods (r >0.90).

④ It fits into automated workflows – the simple add‑mix‑read steps are compatible with liquid handlers and robotic systems, enabling true high‑throughput screening for drug discovery.

⑤ It's backed by Abbkine's quality commitment – each lot is QC‑tested for linearity, sensitivity, and precision, and the company provides detailed technical support and a 30‑day satisfaction guarantee .

Ready to decode the lipogenic flux driving cancer progression, NAFLD, or metabolic syndrome? The CheKine™ Micro Fatty Acid Synthetase (FAS) Activity Assay Kit (KTB2240) delivers gold‑standard accuracy in a microplate‑friendly format – with no radioactivity, minimal sample consumption, and results in 2 hours. Whether you're profiling tumor metabolism, screening FAS inhibitors, or investigating hepatic steatosis, this kit provides the reliability and scalability your work demands.

🔗 Product reference: KTB2240 (Abbkine) – https://www.abbkine.com/product/chekine-micro-fatty-acid-synthetasefas-activity-assay-kit-ktb2240/
(For research use only. Not for diagnostic or therapeutic procedures. Store at –20°C protected from light; stable for 6 months.)